FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
Center | Date | Time | Location |
---|---|---|---|
CDER | April 25, 2006 April 26, 2006 |
8:00 a.m. - 5:00
p.m. 8:00 a.m. - 5:00 p.m. |
Hilton Washington
DC North |
Agenda:
On April 25, 2006, the committee will meet between 8 a.m. to 5 p.m., to discuss
new drug application (NDA) 21-359 CELLEGESIC (nitroglycerin [NTG] ointment),
0.4% intra-anal, Cellegy Pharmaceuticals, Inc., for the proposed indication
of relief of pain associated with anal fissures.
On April 26, 2006, the committee will meet between 8 a.m. to 12 noon, to discuss the agency's draft recommendations for relabeling of antihypertensive drugs for outcome claims, as a followup to the committee's meeting on June 15, 2005, where the committee discussed class labeling of antihypertensive drugs based on the proximity of their data to outcome trials. Following this, from approximately 1 p.m. to 5 p.m., the committee will discuss the "Placebo in Hypertension Adverse Reaction Meta-Analysis" Study, a meta-analysis of more than 80,000 patients in placebo-controlled trials of antihypertensive medications, which evaluated the risk of irreversible harm in conducting placebo-controlled trials in patients with hypertension.
Background material and meeting information will become available no later than one business day before each meeting day (Simply scroll down to the appropriate committee heading).
Procedure:
Interested persons may present data, information, or views, orally or in writing,
on issues pending before the committee. Written submissions may be made to the
contact person by April 14, 2006. On April 25, 2006, oral presentations from
the public will be scheduled between approximately 8:15 a.m. to 8:45 a.m. On
April 26, 2006, oral presentations from the public will be scheduled between
approximately 8:15 a.m. to 8:45 a.m. and 1 p.m. to 1:30 p.m.. Time allotted
for each presentation may be limited. Those desiring to make formal oral presentations
should notify the contact person before April 14, 2006, and submit a brief statement
of the general nature of the evidence or arguments they wish to present, the
names and addresses of proposed participants, and an indication of the approximate
time requested to make their presentation. Persons attending FDA's advisory
committee meetings are advised that the agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings
and will make every effort to accommodate persons with physical disabilities
or special needs. If you require special accommodations due to a disability,
please contact John Lauttman at least 7 days in advance of the meeting at 301-827-7001.
Contact Person:
Cathy Groupe, Center for Drug Evaluation and Research (HFD-21), Food and Drug
Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane,
Rm. 1093) Rockville, MD 20857, 301-827-7001, e-mail: Cathy.Groupe@fda.hhs.gov
Advisory Committee Telephone Information Line:
Please call the Information Line for up-to-date information on this
meeting, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512533.